Tabellen viser forekomsten af bivirkninger med en hyppighed på > 5% der samtidig er mere hyppige blandt
The table presents adverse reactions that occurred with an incidence ≥ 5% and more frequently among BYETTA-treated patients than insulin- or placebo-treated patients.